Wall Street brokerages forecast that Radius Health Inc (NASDAQ:RDUS) will report sales of $13.71 million for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Radius Health’s earnings, with estimates ranging from $10.42 million to $17.00 million. The firm is expected to issue its next quarterly earnings report on Monday, May 7th.
According to Zacks, analysts expect that Radius Health will report full-year sales of $13.71 million for the current year, with estimates ranging from $67.66 million to $108.47 million. For the next fiscal year, analysts forecast that the business will report sales of $169.63 million per share, with estimates ranging from $142.94 million to $204.40 million. Zacks’ sales averages are an average based on a survey of research firms that cover Radius Health.
Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.16). The company had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $7.37 million. During the same quarter last year, the firm posted ($1.22) earnings per share. Radius Health’s revenue for the quarter was up 666.0% compared to the same quarter last year.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 75,000 shares of the stock in a transaction on Friday, February 9th. The shares were bought at an average cost of $34.38 per share, with a total value of $2,578,500.00. Following the completion of the acquisition, the insider now owns 5,773,799 shares in the company, valued at $198,503,209.62. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Growth N. V. Biotech purchased 80,000 shares of the stock in a transaction on Friday, March 2nd. The stock was acquired at an average cost of $32.52 per share, for a total transaction of $2,601,600.00. Following the completion of the acquisition, the insider now owns 5,853,799 shares of the company’s stock, valued at approximately $190,365,543.48. The disclosure for this purchase can be found here. 15.00% of the stock is currently owned by corporate insiders.
Several hedge funds have recently bought and sold shares of RDUS. Consonance Capital Management LP purchased a new stake in shares of Radius Health during the 4th quarter worth about $84,168,000. TimesSquare Capital Management LLC boosted its stake in shares of Radius Health by 184.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after acquiring an additional 1,044,615 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Radius Health during the 3rd quarter worth about $17,236,000. Orbimed Advisors LLC boosted its stake in shares of Radius Health by 59.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock worth $43,284,000 after acquiring an additional 418,700 shares in the last quarter. Finally, Eversept Partners LLC purchased a new stake in shares of Radius Health during the 4th quarter worth about $6,179,000.
Radius Health (RDUS) opened at $35.30 on Wednesday. The company has a current ratio of 5.04, a quick ratio of 4.96 and a debt-to-equity ratio of 0.69. Radius Health has a 12-month low of $24.66 and a 12-month high of $49.16.
ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Anticipate Radius Health Inc (RDUS) Will Post Quarterly Sales of $13.71 Million” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2018/03/14/zacks-brokerages-anticipate-radius-health-inc-rdus-will-post-quarterly-sales-of-13-71-million.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.